Interventional Oncology Market Revenue to Attain USD 6.73 Bn by 2035

Published: 26 Feb 2026

Author: Precedence Research

Share:

Interventional Oncology Market Revenue and Trends 2026 to 2035

The global interventional oncology market revenue was valued at USD 2.94 billion in 2025 and is expected to attain around USD 6.73 billion by 2035, growing at a CAGR of 8.63% during forecast period.The market is experiencing unprecedented growth, driven by the increasing use of interventional oncology and the growing demand for individualized therapies.

What are the Factors Contributing to the Growth of the Interventional Oncology Market?

The increasing incidence of cancer and rising preference for minimally invasive treatments are the major factors accelerating the growth of the market in the coming years. Cancer is one of the leading causes of death globally. The growth of the market is also primarily supported by the increasing shift toward outpatient and ambulatory surgery centers for interventional oncology procedures, which reduces healthcare costs, improves access, and increases patient throughput.

Segment Insights

• By technique, the ablation therapies segment led the interventional oncology market share in 2025, owing to rising demand for minimally invasive procedures. Moreover, the surge in the prevalence of cancer cases and increasing demand for outpatient-based treatments have significantly increased the adoption of ablation procedures.
• By procedure, the vascular interventions segment accounted for the largest market share in 2025, owing to the rising incidence of hepatocellular carcinoma (HCC), the increasing adoption of catheter-based cancer therapies, and the high efficacy of these therapies in treating liver-dominant cancers. Vascular interventions, including transarterial chemoembolization (TACE) and radioembolization (TARE), are leading the market.
• By application, the liver cancer segment contributed the biggest market share in 2025, owing to the rising incidence of hepatocellular carcinoma and rising rates of metastatic liver tumors. Liver cancer is one of the major causes of death globally. TACE, TARE, and ablation procedures are interventional oncology treatments used widely for liver malignancies that cannot be treated surgically.
• By end-user, the hospitals segment held the dominant market share in 2025. Hospitals are the major end users in the market. Hospitals have advanced infrastructure, particularly tertiary care and specialized cancer centers, skilled professionals, and comprehensive cancer care facilities. Hospitals are equipped with sophisticated imaging and navigation technology for precise tumor targeting.

Regional Insights

North America holds the dominant share in the global interventional oncology market. The region’s leadership is driven by the well-established healthcare system, high concentration of specialized cancer centers, increasing prevalence of cancer, surge in healthcare spending, and increasing emphasis on personalized therapies. In addition, the growing popularity of minimally invasive & image-guided treatments and supportive regulatory frameworks substantially increased the adoption of advanced embolization devices and ablation systems in the region.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the rising investments in healthcare infrastructure, high cancer incidence rates, the rising introduction of cost-effective ablation equipment and embolization equipment, growing demand for minimally invasive procedures, increasing number of cancer centers, and favorable government healthcare initiatives.

Interventional Oncology Market Coverage

Recent Developments

• In September 2025, Sirtex Medical, a leading manufacturer of minimally invasive interventional oncology solutions, announced that it had received an expanded CE Mark approval for SIR-Spheres® Y-90 resin microspheres for the treatment of patients with liver cancer. With this expansion, eligibility now covers both primary and secondary liver metastases, increasing patient access to a well-established, targeted therapy.(Source: https://www.prnewswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7798 

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344